Tune in as Dr. Brad Connor describes how the BIOFIRE® FILMARRAY® Gastrointestinal Panel helped facilitate appropriate treatment for a pediatric patient, as well as the benefit of having testing available directly on-site* and how the test may improve patient satisfaction. 

Dr. Connor received an honorarium from bioMérieux for his participation in this podcast.

Learn more here: https://www.biofiredx.com/ 

*The BIOFIRE GI Panel is intended to be run on the BIOFIRE® FILMARRAY® TORCH and the BIOFIRE® FILMARRAY® 2.0 in CLIA-moderate settings.

In this episode, Dr. Brad Connor uses a case study from a returning traveler to illustrate how the BIOFIRE® FILMARRAY® Gastrointestinal Panel helps provide diagnostic certainty by identifying a broad grouping bacteria, viruses, and parasites.

Dr. Connor received an honorarium from bioMérieux for his participation in this podcast.

More about the power of PCR diagnostic testing in point-of-care clinics here.

Join Dr. Brad Connor, a gastroenterologist with a specialty in travel tropical medicine and infectious diseases, as he talks with Connie Zellner, medical education liaison with bioMérieux, about his decision to adopt the BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel and how it has helped him in his gastroenterology clinic.

Dr. Connor received an honorarium from bioMérieux for his participation in this podcast.

More about the power of PCR diagnostic testing in point-of-care clinics here.

In this episode, Dr. Smith explores a case study where he utilized the BIOFIRE® Respiratory Panel to help identify whether a pediatric patient had an exacerbation of allergic rhinitis or a respiratory infection. He wraps up by showing how BIOFIRE respiratory solutions have helped improve patient satisfaction.

This podcast was sponsored by bioMerieux.

More about the power of PCR diagnostic testing in point-of-care clinics here.

This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

In this episode, Dr. Smith delves into two case studies, including one patient with cold urticaria and one with a history of asthma, and describes how the comprehensive BIOFIRE® Respiratory Panel gave him the diagnostic certainty to provide the correct treatment to his patients.

This podcast was sponsored by bioMerieux.

More about the power of PCR diagnostic testing in point-of-care clinics here.

This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Join Dr. Christopher Smith as he talks with Connie Zellner, Medical Education Liaison with bioMérieux, about his decision to adopt the BIOFIRE multiplex respiratory panel and how it has helped him in his asthma and allergy clinic.

This podcast was sponsored by bioMerieux.

More about the power of PCR diagnostic testing in point-of-care clinics here.

This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

How does the syndromic approach impact confidence in treatment plans, as well as parent/patient satisfaction? Join Dr. Jennifer Baird as she discusses this topic with pediatrician Dr. Daniel Bruckner.

This podcast was sponsored by BioFire Diagnostics

More about the power of PCR diagnostic testing in point-of-care clinics here.

This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

BFR0001-3644-01 POC Podcast Episode 3

Join Dr. Jennifer Baird, Global Medical Affairs Scientist at BioFire, as she talks to pediatrician Dr. Daniel Bruckner about how to use the results of a syndromic multiplex panel and the clinical impact that it can have for pediatric patients.

This podcast was sponsored by BioFire Diagnostics

More about the power of PCR diagnostic testing in point-of-care clinics here.

This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

BFR0001-3643-01 POC Podcast Episode 2